Skip to main content

Table 3 Adverse events in the multivitamin and placebo armsa

From: The effect of standard dose multivitamin supplementation on disease progression in HIV-infected adults initiating HAART: a randomized double blind placebo-controlled trial in Uganda

   Multivitamin Placebo P-value
Endpoint Month n # of events (%) n # of events (%)  
Severe anemia (HB <7 g/dL) 6 191 1 (0.5 %) 190 0 0.995b
12 183 0 188 0  
18 181 0 187 1 (0.5 %)  
Nausea 1–3 194 62 (32.0 %) 195 79 (40.5 %) 0.088c
4–6 191 38 (19.9 %) 190 44 (23.2 %)  
10–12 183 25 (13.7 %) 188 33 (17.6 %)  
16–18 181 28 (15.5 %) 187 36 (19.3 %)  
Vomiting 1–3 194 34 (17.5 %) 195 52 (26.7 %) 0.058c
4–6 191 18 (9.4 %) 190 23 (12.1 %)  
10–12 183 15 (8.2 %) 188 22 (11.7 %)  
16–18 181 17 (9.4 %) 187 19 (10.2 %)  
High ALT (>200 IU/I) 6 191 0 190 0 0.496b
12 183 1 (0.5 %) 188 1 (0.5 %)  
18 181 0 187 1 (0.5 %)  
  1. aALT Alanine transaminase, HB Hemoglobin
  2. bFrom Fisher’s exact test for 2 × 2 table
  3. cMixed effects model analysis using logit link